Skip to main
OCS

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding is a biopharmaceutical company with a positive outlook driven by its innovative pipeline of highly-differentiated candidates and a strong potential for success in its upcoming Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema. With its locations in multiple countries and a clear focus on addressing unmet needs in ophthalmic and neuro-ophthalmic conditions, Oculis has the potential for long-term growth and market expansion. Despite potential risks such as trial failures and commercial barriers, the company's solid financials and strategic partnerships make it a strong investment opportunity.

Bears say

Oculis Holding is facing risks to their price target holding their negative outlook. While they have recently initiated the registrational Phase 2/3 PREDICT-1 trial, they still face potential failure in clinical trials and securing regulatory approval in the U.S. for their candidates OCS-01, OCS-02, and OCS-05, which may hinder their ability to achieve commercial success and ultimately affect their stock price. Additionally, the high discount rate and low terminal growth rate used in their DCF analysis suggests a lack of confidence in the company's future prospects and potential dilution risk could further impact their stock.

OCS has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 8 analysts, OCS has a Strong Buy consensus rating as of May 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.